Purpose: Surgical management of carotid restenosis (CR) after carotid endarterectomy (CEA) has been associated with a higher perioperative complication rate than that of primary CEA. We recently used carotid angioplasty-stenting (CAS) as an alternative to operative management in patients who had undergone CEA within three years, and we retrospectively compared these results with those of operative management of CR and the overall results of CEA. Methods: CEA was performed on 1065 adult patients (58% symptomatic, 42% asymptomatic), 62% of whom were men (n = 660) and 38% of whom were women (n = 405), from 1989 to 1997. Before our initiation of a program of CAS, 16 operative procedures (1.9% of CEAs) were performed for CR in 14 adult patients (7 women and 7 men). During the last 20 months, CAS was used in the management of 17 CRs (16 patients; 9 women and 7 men). Results: The 30-day stroke morbidity-death rate for all CEAs (n = 1065) was 1.4%; 11 strokes (1.0%) occurred (4 major strokes with disability and 7 strokes with minor or no disability), and 4 deaths (0.4%) occurred (2 deaths caused by myocardial infarction, 1 caused by intracranial hemorrhage, and 1 caused by stroke). Operative management of CR (n = 16) included patch angioplasty in 12 cases (autologous vein patches in 10 cases and synthetic patches in 2 cases), whereas interposition grafting was used in 4 cases (saphenous vein in 3 instances and synthetic [polytetrafluoroethylene] in one case). No strokes or deaths were observed. One recurrent laryngeal nerve palsy occurred (6.2%). Among the 16 patients undergoing 17 CAS procedures, the technical procedures were accomplished in all patients. No strokes or deaths occurred. No recurrent restenoses (50% or greater) have been identified within or adjacent to the CAS procedures. Conclusion: CR caused by myointimal hyperplasia can be managed by operative techniques or CAS with comparable periprocedural complications. Although long-term follow-up will be required to determine the incidence of recurrent restenosis, CAS may become the preferred procedure in these cases. A randomized clinical trial ultimately will be necessary to determine the role of CAS, as compared with that of operative management. (J Vasc Surg 1999;29:228-38.)
Carotid endarterectomy (CEA) has emerged as the currently preferred treatment of symptomatic 1-3 and asymptomatic 4,5 patients with high-grade extracranial carotid stenoses. Symptomatic or asymptomatic carotid restenosis (CR) after endarterectomy is relatively uncommon and is generally attributed to myointimal hyperplasia during the early postoperative period (within 36 months) or recurrent atherosclerosis thereafter. [6] [7] [8] [9] [10] Surgical management of carotid restenosis is controversial for two major reasons. First, indications for operative management in the asymptomatic patient with high-grade (80% or greater) restenosis are applied conservatively by some, because of the low risk of Carotid restenosis: Operative and endovascular management stroke or progression to total occlusion. 6, 11, 12 Second, reoperation is associated with a marginally increased risk of perioperative neurological events and cranial nerve palsies. 8, 13, 14 Because of these issues, other authors [15] [16] [17] [18] [19] [20] recommend carotid angioplasty-stenting (CAS) as an alternative to operative management. However, lack of efficacy data comparing endovascular management with carotid endarterectomy has created additional controversy about the choice of treatment among specialists seeing patients with CR and those with primary atherosclerotic occlusive disease. 21, 22 We prospectively collected data and intervened with endovascular techniques on patients with symptomatic and asymptomatic (80% or greater) CR caused by myointimal hyperplasia to define technical feasibility and periprocedural outcomes. We also retrospectively analyzed our performance with operative management of carotid occlusive disease and restenosis and compared these data with our recent experience with CAS.
METHODS AND MATERIALS
From 1989 to 1997, CEA was performed on 1065 adult patients; 62% were men (n = 660), with a mean age of 65 years, and 38% were women (n = 405), with a mean age of 62.7 years. Symptomatic lesions were observed in 58% of cases (n = 618), and asymptomatic stenoses were observed in 42% (n = 447). In patients undergoing CEA for symptomatic disease, 81% of the group had high-grade stenoses (70% or greater), whereas 19% of patients had moderate stenoses (50% to 69%). Among symptomatic patients, amaurosis fugax and transient ischemic attack (TIA) constituted the indications for CEA in 65% of patients, whereas stroke with minimal to moderate disability was the indication for CEA in the remaining 35% of patients. CEA was performed in asymptomatic patients for stenoses 80% or greater in 76% of patients and for stenosis of 60% to 79% in 24% of patients. Before we initiated a program of CAS for restenosis, 16 operative procedures were performed for CR in 14 adult patients (seven men and seven women), with a mean age of 64.5 years. Two patients had bilateral CRs, whereas 12 other patients had unilateral restenotic lesions. Nine of the lesions were symptomatic, and seven were asymptomatic. Indications for the patients' prior CEAs were symptomatic disease in 10 cases and asymptomatic stenoses in six cases. Patch angioplasty had been used in nine of the 16 earlier operations, and primary closure had been used in seven procedures. Early operations were performed in nine patients (within 36 months of the original CEA), and thereafter in seven patients (more than 36 months postoperatively).
During the last 20 months (September 1996 through May 1998), 17 CRs (16 patients) were identified and treated by CAS. All symptomatic and asymptomatic (80% or greater) patients with CR were treated with CAS, and no patients were treated operatively during this period. One patient was treated for bilateral restenoses after staged bilateral 
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CEAs, whereas 15 patients were treated for unilateral restenoses. There were nine women and seven men in this group, with a mean age of 66.3 years. The mean interval between CEA and CAS was 13.7 months, with the earliest procedure performed 5 months after surgery and the latest performed 31 months after surgery. Eight patients had sympto-matic restenoses (amaurosis fugax or TIA in seven and stroke in one), and eight patients were asymptomatic. Indications for their original CEAs were seven symptomatic and nine asymptomatic highgrade stenoses. More than half of these patients (n = 10, 11 recurrent stenoses) were referred from other institutions. Data on these patients are summarized in Table I . Technical considerations in performance of CAS are outlined in Table II . Examples of preprocedural and postprocedural results (Figs 1 and 2) are presented and demonstrate placement of an 8 or 10 mm × 20 mm WallStent (Schneider, Minneapolis, Minn).
In each case, 4 or 5 mm low-profile balloons were used to initially dilate the lesions, followed by placement of appropriately sized stents, with poststent balloon dilatation to obtain the final result. Intravascular ultrasound was used as a means of ensuring adequate apposition of the stent to the arterial wall ( Fig 3) . In these cases and all except one other case, stents were placed across the carotid bifurcation, and patency of all external and internal carotid arteries was demonstrated by means of serial duplex ultrasound scan. The patency of this patient's internal carotid artery after CAS was confirmed by means of a follow-up color Doppler energy scan (Fig 4) .
Transfemoral cannulation was used in all except one CAS procedure (Table II) ease with symptomatic CR 10 months after CEA (patient 12, Table I ). The proximal common carotid artery was explored in the operating room under local anesthesia and cannulated using C-arm fluoroscopy for CAS, as has been recommended by Diethrich. 20 The CAS procedure was accomplished successfully, and the cannulation site was repaired with a vascular suture. All patients underwent placement of a single stent; however, one patient underwent CAS for multiple carotid lesions. This 50-year-old white woman (patient 10, Table I ) had undergone CEA at another institution for TIA five months before CAS. Recurrent symptoms resulted in the identification, by means of angiography, of a common carotid stenosis at the aortic arch and an internal carotid stenosis distal to a restenotic lesion at the upper end of a saphenous vein patch ( Fig 5) used in the original CEA. In this instance, the arch stenosis was dilated, and an attempt made to place a Palmaz stent across the lesion. However, the stent migrated into the common carotid artery, and placement of a WallStent was required to entrap the Palmaz stent and maintain patency of the dilated arch stenosis (Fig 6,A) . A guidewire (0.018 in) was then passed across the proximal and distal internal carotid stenoses. Each stenosis was dilated with a low-profile balloon, and an 8 × 20 mm WallStent was placed from a position just above the distal stenosis across the stenosis at the apex of the vein patch extending into the patch-dilated internal carotid artery (Fig 6,B) .
RESULTS
The 30-day stroke morbidity for all CEAs in this series (n = 1065) was 1.0%; 11 strokes occurred (4 major strokes with disability [0.4%] and 7 instances with minor or no disability [0.6%]), whereas the 30day perioperative mortality was 0.4% (two deaths caused by myocardial infarction, one caused by intracranial hemorrhage, and one caused by stroke). The 30-day combined stroke-death rate was 1.4%. Transient cranial nerve palsies were observed in 3.5% of procedures (n = 37). Five patients returned to the operating room for evacuation of hematomas that were not further complicated. Patch angioplasty was used increasingly during the years of this clinical series (1989, 44%; 1992, 62%; 1996 to 1997, 90%). Operative management of 16 carotid restenoses in 14 patients included the use of patch angioplasty in 12 cases associated with a second endarterectomy in seven instances (autologous vein patches were used in 10 cases, and synthetic patches were used in two cases), whereas interposition grafting was used in four cases (saphenous vein in three instances and synthetic [polytetrafluoroethylene] in one case). During the 30-day postoperative period, no strokes or deaths were observed. One recurrent laryngeal Table I ).
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nerve palsy (6.2%) occurred. Although the patient's voice improved during the six months postoperatively, persistent cord palsy with movement of the cord to the midline was observed by means of indirect laryngoscopy. During a mean follow-up of 30 months, no deaths were reported; one patient (6.2%) sustained a minor stroke caused by carotid occlusion after an earlier demonstration of a patent postoperative artery, and an asymptomatic recurrent restenosis of 60%, which is being reevaluated for progression every six months by means of duplex ultrasound scan, developed in one patient (6.2%). In 16 patients undergoing 17 CAS procedures, the technical protocol for CAS (Table II) was accomplished in all patients. Immediate postprocedural hypotension and bradycardia were observed in 2 of 17 procedures (12%). One patient became hypotensive to a systolic pressure of 90 to 110 mm Hg in a period of 3 to 4 hours and required intravenous vasopressors, whereas the other patient responded to an additional dose of Atropine without requiring pressor agents. No additional sequelae occurred in these patients, and all patients were discharged on the first day after the CAS procedure. During the 30-day periprocedural period, no neurological complications or deaths occurred. During the clinical follow-up (mean, 11 months), patients underwent duplex ultrasound scan at three-month to six-month intervals. No external carotid arteries thrombosed during the postprocedural period. Restenosis was identified in one patient as a 40% area reduction within the midportion of the stent; further intervention was not recommended. The one patient undergoing placement of two separate stents, one at the aortic arch and one at the internal carotid artery, demonstrated poor apposition of the stent to the arterial wall in the distal portion of the patch-dilated internal carotid artery. Malpositioning of the stent was confirmed by means of a follow-up duplex scan (Fig 7) ; however, no thrombus or intimal hyperplastic response was observed during the initial follow-up period.
DISCUSSION
CR after endarterectomy has been studied extensively after an initial report on the low incidence of symptomatic restenosis. 7 Although absolute rates of restenosis (50% or greater) have been documented to occur in 6% to 14% of patients [23] [24] [25] [26] after CEA, accompanying neurological events have been reported in only 1% to 5% of these patients. The incidence of restenosis is variable and is in part dependent on the definition of restenosis and the technique used to calculate its incidence. DeGroote and associates 27 emphasized the importance of using life-table methods as a means of determining the incidence of restenosis. Calculation of an absolute restenosis rate (arteries with restenotic lesions/total carotid proce- Table I ). B, A second WallStent that was placed in the internal carotid after dilatation of proximal and distal stenoses. A stenosis, which was not treated, is also seen in the left midsubclavian artery.
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February 1999 dures) will generally underestimate the incidence of restenosis, because it is independent of the duration and frequency of clinical follow-up. However, with life-table methods, the probabilities of developing restenosis (50% or greater) seven years after CEA has been reported as 32% and 31% in two clinical series. 11, 27 Regression of restenotic lesions also has been defined by means of duplex ultrasound scan and has been estimated to be as much as 10%. 11 These data emphasize the value of serial noninvasive testing after CEA, particularly during the first few years postoperatively. However, the heterogeneity of published results on restenosis and operative complications 28 suggests that much better data are needed if we are to arrive at reliable estimates of these complications. Although the risk of restenosis was highest during the first few years after CEA and low thereafter, the recommended frequency of noninvasive testing after CEA remains controversial. 11, 12, 23, 25, 29 However, we recommend noninvasive testing of patients at 6month to 12-month intervals during the first few years after CEA. Thereafter, performance is based on the development of cervical bruits and nonspecific or lateralizing neurological symptoms, rather than routine screening. Patients with symptomatic or highgrade (80% or greater) asymptomatic stenosis are then referred for intervention. We have restricted our clinical experience with CAS to restenoses identified within three years of CEA. Restenoses within this period are likely to be hyperplastic stenoses, which are characterized by smooth, generally nonulcerated surfaces. Although we currently agree with the recent American Heart Association Science Advisory 30 that CAS should not be used routinely for primary atherosclerotic disease unless it is part of a clinical trial, expanding the use of CAS to management of myointimal hyperplastic restenoses seemed reasonable. Results from our series confirm that CAS is safe and effective and that its periprocedural complications are comparable with operative intervention. Further follow-up will better define the incidence of postprocedural recurrent restenosis. Provided the recurrent restenosis rates are low and their subsequent interventions by means of endovascular methods are not associated with additional complications, CAS may become the preferred treatment of myointimal hyperplastic restenoses.
Operative management for CR was first outlined by Stoney and String. 7 These authors reported on the treatment of 29 patients, 5 months to 13 years after CEA. Second endarterectomies were performed in 10 atherosclerotic restenoses, with vein patches used in 8 additional cases; vein patches were used alone in 10 instances, and vein graft replacement was performed in six cases. One postoperative death (3.4%) occurred because of stroke without other complications in their series of patients. An expanded series of 116 operations for restenosis in the same Table I ). Apposition of the stent to the arterial wall was not achieved, and serial follow-up scans will be required. institution was reported by Bartlett and colleagues 8 and was accompanied by a 4.3% stroke morbidity, with two deaths (1.7%) caused by stroke. Transient cranial nerve palsies were reported in 23 cases (19.8%). Das and colleagues 14 reported the use of patch angioplasty in 59 of 62 operations for restenosis, with a combined stroke-death rate of 4.6% and an incidence of transient cranial nerve palsies of 9.2%. Although Gagne and associates 31 reported no perioperative strokes or deaths in a series of 41 reoperations, late postoperative neurological complications or progression to occlusion occurred in 19.5% of cases. The authors had no explanation for these findings, but recommended close postoperative surveillance. The results of interposition grafting for replacement of the involved segment of carotid artery also have been emphasized in recent years. Treiman and co-authors 13 used interposition saphenous vein grafts in 57 of 162 operations for restenoses performed between 1974 and 1991. The use of vein grafting, however, resulted in a 3.5% perioperative stroke rate, as compared with 1.9% for second CEAs. Edwards and colleagues 32 used interposition vein grafts in 20 of 106 restenoses and reported no strokes or deaths. Although no perioperative strokes or deaths occurred in our series, higher stroke and death rates have generally been reported in larger series of patients undergoing reoperation, as compared with primary CEA.
Analysis of the current clinical series was not intended to provide data on the overall incidence of restenosis, which has been studied previously by our group 27 and others, [6] [7] [8] [9] [10] or to evaluate the impact of technical considerations such as patch angioplasty. [33] [34] [35] Rather, the purpose of this report was to introduce the concept of CAS for the management of CR. Experience and competency in endovascular management of aortoiliac and femoropopliteal lesions has been acquired by our vascular surgical group, 36 and our initial results of CAS appear to be comparable with operative management. The level of experience required to achieve technical proficiency with CAS also has implications for future anticipated clinical trials comparing CEA and CAS. 37 Credentialling of interventionalists and vascular or neurosurgeons, who are skilled in endovascular techniques in other vasculatures, probably requires performance of 15 to 30 CAS procedures. Proctoring of initial cases by a cardiologist or other competent interventionalist is an important prerequisite to initiating a successful program in CAS.
We thank Dr Robert D.G. Ferguson (previously at the University of Tennessee and now head of the Department Dr Patrick J. O'Hara (Cleveland, Ohio). Dr Hobson and colleagues describe a series of 16 patients with 17 early recurrent carotid stenoses, presumably caused by myointimal hyperplasia, treated with angioplasty and stenting, compared with a group of 14 patients with 16 recurrent stenoses treated with surgical repair. There were no early strokes or deaths in either group. There was one cranial nerve injury in the surgical group, one malpositioned stent in the stented group, and one nonhemodynamically significant recurrence in each. The authors concluded that, for restenoses caused by myointimal hyperplasia, angioplasty and stenting is safe and effective and its periprocedural complications are comparable with management by means of operative intervention.
I share the authors' view that angioplasty-stenting probably will have a role in the management of carotid occlusive disease, and this study demonstrates the feasibility of angioplasty-stenting in a small number of patients with early recurrent carotid stenoses presumably caused by myointimal hyperplasia. If these preliminary results are borne out by other, larger studies, carotid angioplastystenting may indeed become a welcome tool, especially if it proves to be safe and effective for patients with neck radiation or high lesions, who are difficult to treat with traditional surgical methods. It clearly obviates the risk of cranial nerve injury, which is nearly 10% after reoperations.
The long-term results will be important, however. It does seem counterintuitive that angioplasty-stenting should be a durable solution for myointimal hyperplasia, because this process is a recurring problem after angioplasty-stenting of the coronary and superficial femoral arteries.
This leads to my first question. Are the authors sure that the lesions in both groups are comparable? Histologic verification of myointimal hyperplasia in the stented group is probably not feasible. Furthermore, 44% of the surgically treated restenoses occurred later than 36 months and, therefore, likely were recurrent atherosclerosis. Did the authors use any special pharmacologic methods to reduce the chance of further recurrence in the stented group?
My major reservation regarding this study, however, has to do with the sample size. The authors acknowledge this problem, which affects nearly all reports dealing with recurrent carotid stenosis, because it is an uncommon problem. I would caution against drawing firm conclusions about the clinical equivalence of the two treatment methods from this study, which seems really to be a pilot study. For example, assuming an event rate of 5%, which DISCUSSION approximates the 4.4% perioperative stroke rate we observed in our own recent report, our statistician calculated that the power of the study reported today to detect a difference in event rate from 5% to 10% at the usual 5% confidence level is only 0.08. This means that the authors' study had only about an 8% chance to detect such a difference if it really did exist. To reliably detect the same difference, a sample size of 900 patients, or about 450 in each group, would be required. Consequently, I'd like to ask the authors how confident they are that their conclusions are really substantiated by their data.
Dr Robert W. Hobson II. Thank you, Dr O'Hara, for your excellent comments and questions. Carotid restenosis is relatively common, and your concerns about the 30% or 35% restenosis rates after coronary stenting being translated to the carotids after these procedures needs to be considered. However, I would suggest that the circulations are probably not comparable. The carotid artery and its cerebral circulation represent a low-resistance circuit with an anatomically larger artery. Although the long-term follow-up is unequivocally necessary, recurrent restenosis rates may be lower after carotid stenting, as compared with coronary stenting.
This presentation describes a small sample size and should be considered as a pilot study. It is not, in any way, comparable with a randomized clinical trial. Furthermore, your computation of sample size requirements is accurate. In fact, it has been estimated that a clinical trial comparing the efficacy of carotid endarterectomy and angioplastystenting for atherosclerotic disease would require a sample size as large as 2,200 procedures. Clearly, our sample of 33 restenoses managed by means of operative and endovascular techniques is not adequate to answer the question, and yet these initial results are important when considering options for patient care. I'm not suggesting that at this time we proceed to refer patients for angioplasty, unless the surgeon thinks the reoperative case would be associated with a higher risk. Of our 17 most recent cases, 10 patients (11 procedures) have been referred from other institutions-a fair number of our colleagues are avoiding reoperation in this group of patients.
Regarding the periprocedural antiplatelet protocol, patients receive aspirin and Ticlid for 48 hours before the procedure, maintain both medications for three weeks, and then continue with aspirin only. Other antiplatelet agents may be available in the future, but, as far as I know, they've never been tested or studied for carotid occlusive disease.
Again, I appreciate your comments about rushing to judgment on a small sample size. We agree that surgical management of this condition continues to yield excellent results. We should be cautious about adopting this new procedure.
Thank you. Dr William D. Jordan (Birmingham, Ala). Thank you, Dr Hobson. I enjoyed the presentation. I need to ask you to consider some data that we presented at the Peripheral Vascular meeting in January of this year, in which we reviewed the UAB experience of 28 patients who had angioplasty-stenting for recurrent stenosis. We had 5 events in that group that lasted more than 24 hours, so 5 strokes. All 5 of those patients were the recurrent variety that was present greater than 5 years after their initial endarterectomy. So, I can congratulate you on appropriately selecting a better group.
I would like to ask a question about the selection of the early variety of recurrent stenosis, that is, less than 2 years. It took you basically 7 years to recruit patients in the surgical group and come up with about 2 patients per year. Now, if you look at the newer period, you recruited basically 12 patients a year, a much higher accrual rate. It makes me wonder if we are falling prey to the "oculostenotic reflex" and dilating lesions that previously we were watching, that is, dilating them only because they're there to see.
Dr Hobson. Thank you for your comments. A higher complication rate probably will be observed in patients with carotid restenoses beyond 5 years. Because these lesions are generally recurrent atheromas, artheroembolic episodes should be more common and neurological event rates should be higher. We have restricted our activities to what we consider to be low-risk lesions that are probably unassociated with ulceration in most instances.
You also commented on the rapidity with which we have acquired patients. The 16 operative procedures, recruited from some 840 of 1065 endarterectomies performed during the first five years of this reported clinical experience constituted 1.9% of the surgical cases. However, the 17 cases treated by means of angioplasty-stenting since the fall of 1996 include six cases from our practice and 11 cases referred from other institutions. This accounts for the differences in rates of recruitment, because the more recent experience included the referral cases.
Dr Kevin G. Burnand (London, UK). Dr Hobson, I'm sure you know the question that I'm going to ask is about the symptoms of the stenosis. How did you justify recommending angioplasty-stenting to patients with symptomless stenoses when you didn't know the longterm risks of the procedure? In a recent review in the British Journal of Surgery in which we looked at all the world literature, we could find very little evidence that these patients went on to have any problems. Although it was relatively straightforward, I presume, to enroll people with symptomatic restenosis, how on earth did you get them to consent to have a dilatation of a symptomless restenosis? Dr Hobson. Thank you for your comments and question. We are, of course, familiar with your review paper on this topic in the British Journal of Surgery. You emphasized a conservative approach to the asymptomatic patient with carotid restenosis. Although no prospective data on the risk of restenosis are available, we adopted a recommendation for operative intervention when an asymptomatic restenosis was an 80% or greater diameter-reducing stenosis. Based on our results with operative intervention in these cases, we regarded this as a reasonable decision, and therefore, we February 1999 also decided to consider these patients for endovascular interventions. Having established this threshold for operative intervention, we informed the patient of our recommendation for operation or angioplasty-stenting. Typical of our experience with aortoiliac occlusive disease, our patients universally chose angioplasty.
It is also our opinion that we are approaching clinical equipoise on this question. As defined by Freedman (Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5), when different specialists refer their patients with the same disease for different treat-ments, it may then be ethical to conduct a randomized clinical trial that should document the incidence of restenosis and its associated neurological events. Two groups have submitted grant applications to the National Institutes of Health to compare the efficacy of carotid endarterectomy and angioplasty-stenting. Until such a trial is conducted, recommendations for clinical management will continue to be based on anecdotal data-that is, your review suggesting conservative management and our report recommending an operative or endovascular approach.
